Inflammation strong predictor of recurrent CV events in CKD
In the CANTOS trial, researchers analyzed data from 9,151 adults with a history of MI and an elevated high-sensitivity C-reactive protein already treated with guideline-directed lipid lowering therapy (baseline LDL, 82 mg/dL) who were assigned canakinumab (Novartis) or placebo.

For the new analyses, researchers compared the relative contributions of residual cholesterol risk, as measured by LDL and non-HDL, and residual inflammatory risk, as measured by hsCRP and interleukin-6, as determinants of recurrent major adverse CV events, CV death or all-cause mortality. Results were stratified by baseline estimated glomerular filtration rate (eGFR) above or below 60 mL/min/1.73m2. Participants were followed for up to 5 years.

The data show that residual inflammatory risk plays a substantial role in determining the risk for recurrent CV events among patients with ASCVD and impaired kidney function.